Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2016 Apr;37(4):269-72.
doi: 10.3760/cma.j.issn.0253-2727.2016.04.002.

[Comparison of prognostic models for patients with early-stage diffuse large B-cell lymphoma]

[Article in Chinese]
Weiping Liu  1 , Xiaopei Wang, Chen Zhang, Yan Xie, Ningjing Lin, Meifeng Tu, Lingyan Ping, Zhitao Ying, Lijuan Deng, Huiying Huang, Meng Wu, Yingli Sun, Tingting Du, Xin Leng, Ning Ding, Wen Zheng, Yuqin Song, Jun Zhu
Affiliations
Comparative Study

[Comparison of prognostic models for patients with early-stage diffuse large B-cell lymphoma]

[Article in Chinese]
Weiping Liu et al. Zhonghua Xue Ye Xue Za Zhi. 2016 Apr.

Abstract
in English, Chinese

Objective: To compare the prognostic value of different models in patients with early-stage diffuse large B-cell lymphoma (DLBCL).

Methods: Early-stage DLBCL patients diagnosed from January 2000 to December 2012 were analyzed retrospectively. All patients received with at least 2 cycles of immunochemotherapy R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) with or without radiotherapy. The prognostic value of international prognostic index (IPI) , revised IPI (R-IPI) and enhanced IPI (NCCN-IPI) was compared.

Results: Ninety-seven cases of early-stage DLBCL were included in the study. The median age was 58 years (15-88 years) with a median follow-up of 34.7 months (range 7.3-77.4 months). The expected 5-year overall survival (OS) for entire group was 82%. There was no patient in the high risk group according to IPI or NCCN-IPI. According to IPI, the 5-year OS in the low, low intermediate, high intermediate risk groups were 95%, 38% and 60%, respectively. According to R-IPI, the 5-year OS in the very good, good, and poor risk groups were 93%, 75% and 60%, respectively. According to NCCN-IPI, the 5-year OS in the low, low intermediate, high intermediate risk groups were 92%, 85% and 29%, respectively.

Conclusion: NCCN-IPI would be of an ideal prognostic model for early-stage DLBCL patients.

目的: 探讨不同分层方法对早期弥漫大B细胞淋巴瘤（DLBCL）患者预后的价值。

方法: 回顾性分析2007年1月至2012年12月所诊断的97例初治Ⅰ/Ⅱ期DLBCL患者资料，所有患者至少接受2个周期R-CHOP（利妥昔单抗、环磷酰胺、多柔比星、长春新碱、泼尼松）方案免疫化疗。比较国际预后指数（IPI）、修订国际预后指数（R-IPI）、强化国际预后指数（NCCN-IPI）的预后价值。

结果: 97例患者中男50例，女47例，中位年龄58（15~88）岁。中位随访34.7（7.3~77.4）个月，全组患者的预计5年总生存（OS）率为82%。IPI分层中，低危、低中危和高中危组患者的5年OS率分别为95%、38%和60%（P<0.001）；R-IPI分层中，预后非常好、良好和差组患者的5年OS率分别为93%、75%和60%（P=0.226）；NCCN-IPI分层中，低危、低中危和高中危组患者5年OS率分别为92%、85%和29%（P<0.001）。

结论: NCCN-IPI是早期DLBCL患者的理想预后指标。

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. [No authors listed] A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project[J] N Engl J Med. 1993;329(14):987–994. - PubMed
    1. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP[J] Blood. 2007;109(5):1857–1861. - PubMed
    1. Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era[J] Blood. 2014;123(6):837–842. doi: 10.1182/blood-2013-09-524108. - DOI - PMC - PubMed
    1. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma[J] J Clin Oncol. 2007;25(5):579–586. - PubMed
    1. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20[J] Blood. 1994;83(2):435–445. - PubMed

Publication types